Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

929.51 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 722
Open 929.51
Bid (Size) 925.00 (2)
Ask (Size) 932.00 (1)
Prev. Close 929.51
Today's Range 929.51 - 929.51
52wk Range 547.61 - 972.53
Shares Outstanding N/A
Dividend Yield 0.49%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana. 
Via Talk Markets
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe
Eli Lilly invests £279M in the UK to boost life sciences, while its Alzheimer's drug, donanemab, faces European regulatory hurdles amid ongoing trials and safety concerns. 
Via Benzinga

Performance

YTD
+56.96%
+56.96%
1 Month
+0.65%
+0.65%
3 Month
-2.20%
-2.20%
6 Month
+23.81%
+23.81%
1 Year
+50.74%
+50.74%

More News

Read More
Hims & Hers Health Stock Is Popping Monday: What's Behind The Move?
Via Benzinga
Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug
Via Investor's Business Daily
Topics Lawsuit
Exposures Financial Legal Product Safety
More Patients On Eli Lilly's Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson's Drug
Via Benzinga
'Most Widely Hated' Bull Market Reaches 2-Year Milestone: Top 20 S&P 500 Stocks Driving The Rally
Via Benzinga
Topics Stocks
Exposures US Equities
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
Via Investor's Business Daily
Which Pharma Stock Is the Better Bargain Buy: Pfizer or Eli Lilly?
Via The Motley Fool
FDA To Reassess Ban On Cheaper, Compounded Versions of Eli Lilly Weight Loss Drugs
Via Benzinga
Exposures Product Safety
3 No-Brainer Growth Stocks to Buy in October
Via The Motley Fool
Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
Via MarketBeat
Got $500? 2 Magnificent Growth Stocks to Buy and Hold Forever
Via The Motley Fool
Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12
Via Talk Markets
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Via Benzinga
Criminal Networks Cash In On Demand For Weight Loss Drugs, Authorities Say
Via Benzinga
Topics Law Enforcement
Exposures Legal
Sustainability Of Energy Stocks Is Clouded By 2024 Election Uncertainty
Via Investor's Business Daily
Warning: This Skyrocketing Stock Has a Hidden Risk
Via The Motley Fool
FTC Faces Pressure to Block Novo Nordisk-Catalent Merger Over Antitrust Fears
Via Benzinga
Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves
Via Benzinga
Exposures Product Safety
Top 3 Stocks with Explosive Call Option Activity: What to Watch
Via MarketBeat
2 No-Brainer Dividend Growth Stocks to Buy Right Now
Via The Motley Fool
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Via Benzinga
CVS, UnitedHealth Request FTC Chair Recusal Amid Ongoing Pharmacy Benefit Managers Lawsuit
Via Benzinga
What's Going With WeightWatchers Stock On Wednesday?
Via Benzinga
Exposures Product Safety
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
Via MarketBeat
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.